JPWO2019048489A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019048489A5
JPWO2019048489A5 JP2020513799A JP2020513799A JPWO2019048489A5 JP WO2019048489 A5 JPWO2019048489 A5 JP WO2019048489A5 JP 2020513799 A JP2020513799 A JP 2020513799A JP 2020513799 A JP2020513799 A JP 2020513799A JP WO2019048489 A5 JPWO2019048489 A5 JP WO2019048489A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020513799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532572A (ja
JP2020532572A5 (https=
JP7277439B2 (ja
Publication date
Priority claimed from PCT/EP2017/072386 external-priority patent/WO2019048040A1/en
Application filed filed Critical
Publication of JP2020532572A publication Critical patent/JP2020532572A/ja
Publication of JPWO2019048489A5 publication Critical patent/JPWO2019048489A5/ja
Publication of JP2020532572A5 publication Critical patent/JP2020532572A5/ja
Priority to JP2023076556A priority Critical patent/JP2023103315A/ja
Application granted granted Critical
Publication of JP7277439B2 publication Critical patent/JP7277439B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020513799A 2017-09-06 2018-09-05 癌の診断に有用な抗体 Active JP7277439B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023076556A JP2023103315A (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/072386 2017-09-06
PCT/EP2017/072386 WO2019048040A1 (en) 2017-09-06 2017-09-06 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
PCT/EP2018/073883 WO2019048489A1 (en) 2017-09-06 2018-09-05 ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076556A Division JP2023103315A (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Publications (4)

Publication Number Publication Date
JP2020532572A JP2020532572A (ja) 2020-11-12
JPWO2019048489A5 true JPWO2019048489A5 (https=) 2022-04-27
JP2020532572A5 JP2020532572A5 (https=) 2022-04-27
JP7277439B2 JP7277439B2 (ja) 2023-05-19

Family

ID=59858709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513799A Active JP7277439B2 (ja) 2017-09-06 2018-09-05 癌の診断に有用な抗体
JP2023076556A Pending JP2023103315A (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023076556A Pending JP2023103315A (ja) 2017-09-06 2023-05-08 癌の診断に有用な抗体

Country Status (15)

Country Link
US (3) US11279757B2 (https=)
EP (2) EP4512830A3 (https=)
JP (2) JP7277439B2 (https=)
KR (2) KR20230107371A (https=)
CN (3) CN118852435A (https=)
AU (2) AU2018327587B2 (https=)
BR (1) BR112020003694B1 (https=)
CA (1) CA3073157A1 (https=)
ES (1) ES2998108T3 (https=)
IL (2) IL293017A (https=)
MX (2) MX393242B (https=)
PL (1) PL3679069T3 (https=)
SG (1) SG11202000961SA (https=)
WO (2) WO2019048040A1 (https=)
ZA (1) ZA202000851B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
KR20230171465A (ko) 2021-04-22 2023-12-20 아스텔라스세이야쿠 가부시키가이샤 항cldn4-항cd137 이중특이성 항체
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
TW202542202A (zh) * 2024-01-04 2025-11-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫療用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
CA2882022A1 (en) * 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
US20100129929A1 (en) * 2006-07-27 2010-05-27 Roberto Polakewicz Tyrosine Phosphorylation Sites
MY162056A (en) * 2006-10-12 2017-05-31 Univ Tokyo Diagnosis and treatment of cancer using anti -ereg antibody
WO2009028663A1 (ja) * 2007-08-30 2009-03-05 Kyowa Hakko Kirin Co., Ltd. 抗Claudin-3抗体
CN101918450A (zh) * 2008-01-11 2010-12-15 国立大学法人东京大学 抗cldn6抗体
NZ716587A (en) 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
EP2322555A1 (en) * 2009-11-11 2011-05-18 Ganymed Pharmaceuticals AG Antibodies specific for claudin 6 (CLDN6)
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
US9321842B2 (en) * 2011-05-13 2016-04-26 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
GB201607534D0 (en) * 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2019048040A1 (en) 2017-09-06 2019-03-14 Ganymed Pharmaceuticals Gmbh ANTIBODIES USEFUL IN THE DIAGNOSIS OF CANCER

Similar Documents

Publication Publication Date Title
JP2020532572A5 (https=)
CN112094342B (zh) 与SARS-CoV-2 RBD结合的羊驼源纳米抗体
AU2016209247B2 (en) Non-immunogenic single domain antibodies
CN114746440B (zh) 新型多肽复合物
RU2017134909A (ru) Новая форма IL33, мутировавшие формы IL33, антитела, анализы и способы их применения
JP2018516853A5 (https=)
JP7820383B2 (ja) グリピカン－３およびｔ細胞受容体を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド
JP2010502183A5 (https=)
EP2760889A1 (en) Antibodies against tl1a and uses thereof
JP2005518789A5 (https=)
AU2015358266A1 (en) TDP-43-binding polypeptides useful for the treatment of neurodegenerative diseases
JP2014158485A5 (https=)
TWI815136B (zh) 一種雙特異性抗體及其用途
JP2017524362A5 (https=)
JPWO2019048489A5 (https=)
JP2017509323A5 (https=)
JP2023518225A (ja) ムチン１７に対する抗体及びその使用
JPWO2022042488A5 (https=)
US20240019424A1 (en) Method for resolving complex, multistep antibody interactions
JP2023159299A (ja) α－シヌクレインプロトフィブリル結合抗体
CN102132143B (zh) 筛选高亲和力抗体的方法
JPWO2021133723A5 (https=)
KR20250153801A (ko) Il-36r 결합 단백질 및 이의 의학적 용도
CN119546645A (zh) 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
CN114249821A (zh) 与SARS-CoV-2 RBD结合的羊驼源纳米抗体